Skip to main content
Top
Published in: Osteoporosis International 1/2021

01-01-2021 | Glucocorticoid | Viewpoints

A pragmatic proposal for triaging DXA testing during the COVID-19 global pandemic

Authors: H.R. Sapkota, A. Nune, J. Bateman, S. Venkatachalam

Published in: Osteoporosis International | Issue 1/2021

Login to get access

Abstract

The COVID-19 pandemic has resulted in huge disruption to healthcare provision, including to dual-energy X-ray absorptiometry (DXA) imaging. Increased waiting lists for DXA from the pandemic mean potential long and uncertain delays in treatment for osteoporosis. To address these increased waiting lists, we propose a rapid, simple, one-stop algorithm incorporating medication use (aromatase inhibitor, corticosteroid) and clinical risk stratification supplementing a standard FRAX assessment. Our pragmatic algorithm produces a recommendation to treat empirically, image with DXA, or observe. If applied, we model a significant reduction in DXA scan requirements with a corresponding reduction in treatment delays for those awaiting DXA. We estimate this will reduce DXA scan numbers by about 50%, whilst pragmatically ensuring those with the highest clinical need correctly receive treatment without delay. This algorithm will help many clinicians including general practitioners/family physicians prioritise DXA when they may not always have the expertise to make this judgement based on clinical information alone. Although we have used UK guidelines as an example, this approach is flexible enough for adaptation by other countries based on their local guidelines, licensing, prescribing requirements, and DXA waiting list times. There are some limitations to our proposal. However, it represents one way of managing the uncertainty of the current COVID-19 pandemic.
Literature
1.
13.
go back to reference Buckley L, Guyatt G, Fink H et al (2017) American College of Rheumatology guideline for the prevention and treatment of glucocorticoid-induced osteoporosis [published correction appears in Arthritis Rheumatol. 2017 Nov;69(11):2246]. Arthritis Rheumatol 69(8):1521–1537. https://doi.org/10.1002/art.40137CrossRefPubMed Buckley L, Guyatt G, Fink H et al (2017) American College of Rheumatology guideline for the prevention and treatment of glucocorticoid-induced osteoporosis [published correction appears in Arthritis Rheumatol. 2017 Nov;69(11):2246]. Arthritis Rheumatol 69(8):1521–1537. https://​doi.​org/​10.​1002/​art.​40137CrossRefPubMed
21.
go back to reference Gittoes NJ, Criseno S, Appelman-Dijkstra NM et al (2020) Endocrinology in the time of COVID-19: management of calcium disorders and osteoporosis. Eur J Endocrinol. https://doi.org/10.1530/EJE-20-0385 EJE-20-0385. [published online ahead of print, 2020 May 1] Gittoes NJ, Criseno S, Appelman-Dijkstra NM et al (2020) Endocrinology in the time of COVID-19: management of calcium disorders and osteoporosis. Eur J Endocrinol. https://​doi.​org/​10.​1530/​EJE-20-0385 EJE-20-0385. [published online ahead of print, 2020 May 1]
24.
go back to reference Early Breast Cancer Trialists’ Collaborative Group (EBCTCG) (2015) Adjuvant bisphosphonate treatment in early breast cancer: meta-analyses of individual patient data from randomised trials. Lancet 386(10001):1353–1361. https://doi.org/10.1016/S0140-6736(15)60908-4 Erratum in: Lancet. 2016 Jan 2;387(10013):30. Erratum in: Lancet. 2017 Jun 24;389(10088):2472CrossRef Early Breast Cancer Trialists’ Collaborative Group (EBCTCG) (2015) Adjuvant bisphosphonate treatment in early breast cancer: meta-analyses of individual patient data from randomised trials. Lancet 386(10001):1353–1361. https://​doi.​org/​10.​1016/​S0140-6736(15)60908-4 Erratum in: Lancet. 2016 Jan 2;387(10013):30. Erratum in: Lancet. 2017 Jun 24;389(10088):2472CrossRef
25.
go back to reference Gnant M, Pfeiler G, Steger G et al (2019) Austrian Breast and Colorectal Cancer Study Group. Adjuvant denosumab in postmenopausal patients with hormone receptor-positive breast cancer (ABCSG-18): disease-free survival results from a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol 20(3):339–351. https://doi.org/10.1016/S1470-2045(18)30862-3CrossRefPubMed Gnant M, Pfeiler G, Steger G et al (2019) Austrian Breast and Colorectal Cancer Study Group. Adjuvant denosumab in postmenopausal patients with hormone receptor-positive breast cancer (ABCSG-18): disease-free survival results from a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol 20(3):339–351. https://​doi.​org/​10.​1016/​S1470-2045(18)30862-3CrossRefPubMed
Metadata
Title
A pragmatic proposal for triaging DXA testing during the COVID-19 global pandemic
Authors
H.R. Sapkota
A. Nune
J. Bateman
S. Venkatachalam
Publication date
01-01-2021
Publisher
Springer London
Published in
Osteoporosis International / Issue 1/2021
Print ISSN: 0937-941X
Electronic ISSN: 1433-2965
DOI
https://doi.org/10.1007/s00198-020-05722-4

Other articles of this Issue 1/2021

Osteoporosis International 1/2021 Go to the issue